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Background: Acute schistosomiasis constitutes a rare but serious condition in individuals experiencing their first
prepatent Schistosoma infection. To circumvent costly and time-consuming diagnostics, an early and rapid
diagnosis is required. So far, classic diagnostic tools such as parasite microscopy or serology lack considerable
sensitivity at this early stage of Schistosoma infection. To validate the use of a blood based real-time polymerase
chain reaction (PCR) test for the detection of Schistosoma DNA in patients with acute schistosomiasis who acquired
their infection in various endemic regions we conducted a European-wide prospective study in 11 centres
specialized in travel medicine and tropical medicine.
Methods: Patients with a history of recent travelling to schistosomiasis endemic regions and freshwater contacts,
an episode of fever (body temperature ≥38.5°C) and an absolute or relative eosinophil count of ≥700/μl or 10%,
were eligible for participation. PCR testing with DNA extracted from serum was compared with results from
serology and microscopy.
Results: Of the 38 patients with acute schistosomiasis included into the study, PCR detected Schistosoma DNA in
35 patients at initial presentation (sensitivity 92%). In contrast, sensitivity of serology (enzyme immunoassay and/or
immunofluorescence assay) or parasite microscopy was only 70% and 24%, respectively.
Conclusion: For the early diagnosis of acute schistosomiasis, real-time PCR for the detection of schistosoma DNA in
serum is more sensitive than classic diagnostic tools such as serology or microscopy, irrespective of the region of
infection. Generalization of the results to all Schistosoma species may be difficult as in the study presented here
only eggs of S. mansoni were detected by microscopy. A minimum amount of two millilitre of serum is required for
sufficient diagnostic accuracy.Background
Schistosomiasis is a parasitic infection with trematode flat-
worms of the genus Schistosoma. According to the World
Health Organization (WHO) 200 million people in at least
76 countries are affected, most of them located in tropical
and subtropical regions [1]. Most infections are attributable
to three species: Schistosoma mansoni, S. haematobium,
and S. japonicum [2]. The courses of human infections can* Correspondence: d.wichmann@uke.de
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distribution, and reproduction in any mediumbe divided into acute and chronic forms. Acute schistosom-
iasis, also known as Katayama syndrome [3,4], constitutes a
fulminant allergic reaction with fever and eosinophilia and
may be accompanied by skin, pulmonary, abdominal or
even neurological symptoms. In general, these clinical
courses are seen in patients experiencing their first
Schistosoma infection and reflect an early immunological
reaction against developing young worms during prepa-
tency [5]. Accordingly, acute schistosomiasis is usually seen
in non-immune travellers returning from Schistosoma en-
demic countries. Considering the broad differential diagno-
sis of fever and eosinophilia, an early and rapid diagnosis istral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
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consuming diagnostic procedures. However, acute schisto-
somiasis constitutes a diagnostic challenge as classical tools
often fail to detect the parasite at this early stage of infec-
tion. Parasite microscopy following Katz-Kato smears or
concentration techniques for helminth eggs, lack sensitivity,
in particular, in individuals with a low parasite burden and
during the prepatent period [6]. In settings with low trans-
mission rates or in patients with low parasite burden im-
munological tests may be more sensitive than parasite
microscopy [7]. Nevertheless, a substantial number of
patients remain serologically negative at initial presentation
[8,9]. Moreover, the inability of serology to discriminate be-
tween active and past disease limits its clinical value for fol-
low up investigations [10]. The detection of Schistosoma
specific circulating anodic and cathodic antigens (CAA and
CCA) in blood or urine, released by viable adult worms,
has been tested in schistosomiasis endemic regions and
sporadic experiences have been reported for the use in
patients with acute schistosomiasis [11-13]. Because the
sensitivity of these tests greatly depends on the worm bur-
den, they are probably not suited for the diagnosis of schis-
tosomiasis in travellers with rather low worm burden.
Recently, we reported on the development of a new
real-time polymerase chain reaction (PCR) test for the
detection of Schistosoma specific DNA in blood of
infected individuals [14], which revealed excellent per-
formance for the diagnosis of acute schistosomiasis in a
small group of travellers returning from Rwanda [15].
Here we report on a European-wide multicenter study
to evaluate the use of this PCR for the diagnosis of acute
schistosomiasis in larger number of patients returning
from various destinations.Methods
Study design
Evaluation of blood based real-time PCR testing in tra-
vellers returning from schistosomiasis endemic regions
with suspected acute schistosomiasis in 11 specialized
European centres in a prospective study from January
2009 to April 2012. In detail the participating countries
were Belgium, France, Norway and Germany. The sites
are institutions specialised in tropical or travel medicine
and are members of the EuroTravNet (www.istm.org/
eurotravnet/main.html) initiated by The International
Society of Travel Medicine and which represents a col-
laborative network of the European Centre of Disease
Control (ECDC). The study was approved by the
Hamburg Ethics Committee of the Chamber of Physicians
and complied with the Declaration of Helsinki. For the
Oslo site data managing files were slightly modified accord-
ing to local data security requirements, for the other sites
no changes were required.Inclusion criteria
Patients with a history of a recent travel to a schistosom-
iasis endemic region and freshwater contacts, an episode
of fever (body temperature ≥ 38.5°C) and an absolute or
relative eosinophil count of ≥700/μl or ≥10%, were eli-
gible for participation (Group A; n = 38). In addition, 17
patients with high clinical suspect of acute schistosomia-
sis but without an episode of fever were also tested
(Group B). An amount of at least 2 ml of serum was
required for DNA extraction and PCR testing as well as
for Schistosoma serology. Oral informed consent was
obtained from every patient or their legal guardians.
Microscopic parasite detection
Microscopy of faecal or urine samples for the detection
of Schistosoma eggs were done on individual decision of
the attending physician at each centre according to
established in-house protocols. In general, stool samples
were analysed using the formol-ether concentration
technique [16]. For detection of S. haematobium eggs,
urine collected over a period of 24 hours or at least be-
tween 10 am and 2 pm was filtered and processed as
described earlier [17].
Serum and plasma samples
Samples were sent to Hamburg by mail at room
temperature and analysed for anti-Schistosoma specific
antibodies and Schistosoma DNA.
Serology
All patient sera were tested for anti-schistosoma anti-
bodies using an enzyme-immunoassay (EIA) and an
immunofluorescence-assay (IFA), respectively [18,19].DNA preparation and real time PCR
DNA preparation from 2 ml serum was performed at the
Bernhard Nocht Institute for Tropical Medicine, Hamburg,
Germany, using the QIAamp Circulating Nucleic Acid Kit
according to the manufacturers suggestion (Qiagen, Hilden,
Germany). Detection of cell-free Schistosoma DNA was
performed according to a previously published protocol
[14]. The test targets the 121 bp tandem repeat sequence
first described by Hamburger et al. [20] using the primer
sequences SRA1 (CCACGCTCTCGCAAATAATCT) and
SRS2 (CAACCGTTCTATGAAAATCGTTGT) as previ-
ously reported [14]. All PCRs were performed in duplicate.
A test was considered positive when the threshold was
attained within 45 PCR cycles (Ct-value < 45).
Diagnosis and treatment
A patient was considered positive for acute schistosom-
iasis when either microscopy, serology or PCR testing
revealed a positive result. Treatment with Praziquantel
Table 1 Characteristics of patients with acute schistosomiasis fulfilling the inclusion criteria
Patient Region of
exposure
Reason for
travel
Incubation time
[days] (1)
Time to diagnosis
[days] (2)
Eosinophils absolute
[per μl]
PCR Serology Microscopy
1 Rwanda Tourist 57 62 5.400 pos pos S.m.
2 Rwanda Tourist 33 54 2.090 pos (pos) S.m.
3 Mozambique Occupational 28 42 2.860 pos pos Ø
4 Ethiopia Occupational 27 43 2.650 pos Ø Ø
5 Uganda Occupational 38 56 1.920 pos pos Ø
6 Uganda Occupational 20 32 1.600 pos pos n.a.
7 Malawi Tourist 18 20 1.050 pos pos n.a.
8 Mozambique Tourist 35 56 33.050 pos Ø n.a.
9 Yemen Tourist 40 54 1.540 pos pos Ø
10 Malawi Tourist 27 35 980 pos Ø Ø
11(3) Kenya Tourist 94 96 3.220 Ø pos Ø
12 Kenya Tourist 184 302 1.100 pos pos Ø
13 Sudan Occupational 27 33 3.350 pos Ø Ø
14 Tanzania Volunteer 75 88 5.880 pos pos n.a.
15 East Africa Volunteer 127 131 1.760 pos pos Ø
16(4) Kenya VFR 150 210 n.a. pos n.a. S.m.
17 Uganda Tourist 24 27 n.a. pos pos n.a.
18 Malawi Tourist 31 73 3.920 pos Ø n.a.
19 East Africa Volunteer 32 104 4.010 pos pos Ø
20 Malawi Tourist 31 34 1.780 Ø Ø Ø
21 Mali Occupational 23 32 1.140 pos Ø Ø
22 Tanzania Volunteer 62 66 2.800 pos Ø Ø
23 Madagascar Tourist 35 38 2.640 pos pos n.a.
24 Madagascar Occupational 92 261 890 pos pos n.a.
25 Madagascar Occupational 122 152 870 pos pos Ø
26 East Africa Tourist 24 36 3.150 pos pos Ø
27 Tanzania Volunteer 47 76 1.700 pos pos S.m.
28 Tanzania Volunteer 47 80 9.850 pos pos Ø
29 Tanzania Volunteer 62 94 2.310 pos pos Ø
30 Tanzania Volunteer 97 196 2.290 Ø pos Ø
31 Madagsacar Occupational n.a. 160 1.100 pos pos Ø
32 Madagascar Tourist 17 43 1.020 pos pos S.m.
33(5) Ghana VRF 31 69 1.200 pos pos n.a.
34 Madagascar Tourist 23 34 1.210 pos pos n.a.
35 Uganda Tourist 41 53 2.900 pos Ø n.a.
36 Madagascar Tourist 25 42 23.300 pos pos S.m.
37 Ghana Tourist 40 46 1.660 pos pos n.a.
38 Tanzania Tourist 27 119 2.340 pos pos n.a.
(1): Time from exposure to beginning of clinical symptoms.
(2): Time from exposure to diagnostics.
(3): Less than 2 ml of Serum was available for DNA extraction.
(4): Patient evaluated for liver transplantation due to known Hepatitis B Virus infection and eosinophilia after visiting her family.
(5): Patient with meningitis and eosinophils in cerebrospinal fluid, Schistosoma DNA detected by PCR in cerebrospinal fluid.
VFR Visiting relatives and friends.
n.a. Not available.
pos Positive.
Ø Negative.
(pos) Only one of two different serological tests for schistosomiasis shows a positive result.
S.m. eggs of S.mansoni.
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with a positive test result.Results
Thirty-eight patients fulfilled the case definition (Group
A). Four of them had a history of possible previous ex-
posure to Schistosoma-contaminated water but had not
developed symptoms after the first trip. The median
time from the day of possible exposure to the onset of
clinical symptoms and the median time from exposure
to PCR were 35 days (range 12–184 days) and 61 days
(range 20–302 days), respectively. Twelve of the patients
presented within 6 weeks after the suspected exposure,
the time span generally referred to as prepatent stage of
S. mansoni. The median absolute eosinophil count was
2,290 μl-1 (range 870–33,050 μl-1). The various members
of the study population have been travelled to 17 differ-
ent African and Arabic countries with endemic schisto-
somiasis. The median age of the study population was
28 years (range 19 – 66 yr) and 76% were males. Reasons
for travelling included: tourism (48%; n = 19), occupa-
tional travel (23%; n = 9), volunteer (21%; n = 8) and vis-
iting friends and relatives (8%; n = 3). The patients´
characteristics are summarized in Table 1.
Initial real-time PCR testing revealed positive detec-
tion of Schistosoma DNA in 35 patients. Of the
remaining 3 patients with negative PCR results, the first
one was part of a four patients cluster. He had an initial
eosinophil count of 2,290 μl-1 and a positive serology.
The three other patients in this cluster were positive by
means of serology and PCR. All received Praziquantel
early in the course of the disease and subsequently, la-
boratory results normalized and clinical symptoms
resolved. Accordingly, the negative PCR result in this
case was considered as false negative. The second pa-
tient with a negative PCR test result was considered true
negative, since microscopy and serology remained nega-
tive during follow up. The third patient with a negative
PCR test result provided only a small amount of serum
for PCR testing of less than 2 ml. In favour of a conser-
vative estimation we interpreted this result as false nega-
tive because serology was clearly positive and symptoms
resolved after Praziquantel treatment. Thus blood based
real-time PCR was able to detect acute schistosomiasis
in 35 of 37 true positive patients (95%). In contrast, anti-
schistosoma antibodies or Schistosoma eggs were
detected in only 72% and 25%, respectively, of these
patients.
For 8 patients follow-up data were available. Four
patients presented with negative real-time PCR at their
follow up visit. The remaining 4 demonstrated a signifi-
cant decrease in Ct-values. Median follow-up times of
patients with positive PCR test results versus patientswith negative PCR test results were 6 and 18 months re-
spectively (data not shown).
In addition, 17 patients (Group B) with high clinical sus-
pect for acute schistosomiasis but without an episode of
fever were tested (Table 2). The incubation time and the
time from exposure to diagnostic work up was 38 days
(range 14–93 days) and 64 days (range 17–96 days), re-
spectively. Sixteen patients were males. The median age
was 13 years (range: 6 – 60 yr) and the median eosinophil
count was 1,960 μl-1 (range 1,040–14,270 μl-1). The deci-
sion for testing these patients was based on high eosinophil
counts, a history of recent travelling to a schistosomiasis
endemic region and at least one of the following symptoms:
fatigue, gastro-intestinal symptoms, rash or exanthema.
Blood based real-time PCR testing was negative in 5 of
these patients. In these 5 patients, initial serological testing
revealed a positive result in one patient and inconclusive
results in two patients. On follow up visits, all of them were
serologically negative. Microscopic examination of stool
samples was negative in all patients at initial presentation
and during follow up. Of the remaining 12 patients, one
was returning from Togo with positive serology and mi-
croscopy and the other 11 were part of a travel group
returning from Rwanda. In this cluster reported earlier [15],
PCR was positive in all of them, whereas positive serology
or microscopy at initial testing was detected in only 7
of them.
Discussion
To our knowledge this is the first multicenter study on
acute schistosomiasis in travellers residing in non-
endemic countries. Moreover, it constitutes the largest
prospective study on a blood based real-time PCR for
the diagnosis of the disease. The high rate of positive
PCR results within the study population may be in part
attributed to the fact that the participating centres are
well familiar with this otherwise rare disease of acute
schistosomiasis as all centres are specialized in travel
and tropical medicine.
The results presented here support previous findings
that PCR for the detection of Schistosoma DNA in
serum outperforms other diagnostic test such as ser-
ology or microscopy in the early phase of the infection,
particular in the prepatent stage of human schistosomia-
sis [14], as demonstrated by the twelve patients present-
ing within 42 days after the suspected exposure. By PCR,
a correct diagnosis was made in 95% of patients, despite
the heterogeneous characteristics of the study popula-
tion (17 endemic countries - cluster and single patients),
which underlines the robustness of blood base real-time
PCR testing for the diagnosis of acute schistosomiasis.
In addition, PCR was able to exclude active Schistosoma
infections in six patients, of whom 50% were suspected
due to positive serology (1 positive, 2 inconclusive).
Table 2 Characteristics of patients with high suspicion of acute schistosomiasis but without fever
Patient Region of
exposure
Reason for
travel
Incubation time
[days] (1)
Time to diagnosis
[days] (2)
Eosinophils absolute
[per μl]
PCR Serology Microscopy
39 Togo VFR 51 95 6,000 pos pos S.m.
40 Brazil Tourist 39 66 11,640 Ø Ø Ø
41 Guinea Tourist 14 17 1,090 Ø pos Ø
42 Uganda Occupational 38 44 n.a. Ø pos n.a.
43 Egypt Tourist 26 40 1,100 Ø Ø Ø
44 Malawi Tourist 37 40 1,040 Ø (pos) Ø
45 Rwanda Tourist 47 54 2,640 pos Ø S.m.
46 Rwanda Tourist 62 90 14,150 pos pos S.m.
47 Rwanda Tourist 57 62 1,150 pos Ø Ø
48 Rwanda Tourist 93 96 2,860 pos (pos) S.m.
49 Rwanda Tourist 25 54 14,270 pos pos S.m.
50 Rwanda Tourist n.a. 96 11,120 pos pos S.m.
51 Rwanda Tourist n.a. 96 1,960 pos pos Ø
52(3) Rwanda Tourist n.a. 62 1,290 pos Ø Ø
53(3) Rwanda Tourist n.a. 96 1,210 pos (pos) S.m.
54(3) Rwanda Tourist n.a. 96 2,120 pos (pos) Ø
55(3) Rwanda Tourist n.a. 96 1,700 pos pos S.m.
(1): Time from exposure to beginning of clinical symptoms.
(2): Time from exposure to diagnostics.
(3): Persons from cluster, exposed 2 years before at the same location as well, and not previously diagnosed.
VFR Visiting relatives and friends.
n.a. Not available.
pos Positive.
Ø Negative.
(pos) Only one of two different serological tests for schistosomiasis shows a positive result.
S.m. eggs of S.mansoni.
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PCR test system used in this study is highly sensitive
and specific [14]. Accordingly, this test system has sub-
stantial added value for an early and rapid decision mak-
ing to circumvent cost-intensive and time-consuming
diagnostic procedures and to prevent unnecessary ther-
apies. Cost for one PCR test (materials and reagents) are
roughly 2 US$, thus the test is a useful addition in the
differential diagnosis in patients with fever and eosino-
philia after travelling to schistosomiasis endemic coun-
tries but is not generally recommended as a screening
assay for returning travelers.
A considerable disadvantage of classical Schistosoma
diagnostics is the persistence of serologic markers and
egg shedding after successful treatment. Previous studies
in experimentally infected mice [14] suggested that
blood based real-time PCR testing might be suitable not
only for initial diagnosis but also for follow up monitor-
ing. This is further supported by our findings in 8
patients, for whom follow up data were available. These
results suggest a significant decline in Ct-values in re-
sponse to treatment. Clearly negative PCRs are expected
after a longer period of time due to the high sensitivity
of PCR and the carry over of DNA from slowlydegenerating eggs in the tissue. However, for a definite
conclusion on the usefulness of PCR for monitoring of
schistosomiasis treatment the follow-up of a larger num-
ber of patients is required.
The highly repetitive 121 bp DNA fragment used as
target sequence in the real-time PCR assay constitutes
about 12% of the S. mansoni genome [20]. Although
this sequence is detected in S. haematobium and
S. japonicum as well [20,21] sensitivity of PCR for the
latter two species might be reduced. As far as species
could be determined by microscopic egg morphology,
the vast majority of cases in this study were due to
infections by S. mansoni. Thus, our results may not allow
generalization to infections with Schistosoma species
other than S. mansoni. Evaluation of blood based PCR
for the diagnosis of acute schistosomiasis due to
other Schistosoma species such as S. haematobium or
S. japonicum requires further studies. Previous results
with the assay used in this study indicated that the per-
formance of the PCR using the 121 bp tandem target se-
quence on 2 ml serum samples works very well in
S. mansoni infection, but not in S. haematobium and in
S. mekongi infection (Jan Clerinx, personal communica-
tion). Likewise, additional studies are required to evaluate
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chronic schistosomiasis, in particular, in suspected cases
from endemic countries, with a positive serology but nega-
tive parasite microscopy. Moreover, recent studies on, PCR
performed with urine or fecal samples to detect S. haema-
tobium or S. mansoni infection have shown rather promis-
ing results [22-25]. However, further studies are required to
determine, whether urine and/or feces PCR is sensitive to
detect early schistosoma infection as it is the case in
patients with acute schistosomiasis.Conclusion
For the early diagnosis of acute schistosomiasis, real-
time PCR for the detection of Schistosoma DNA in
serum is more sensitive than classic diagnostic tools
such as serology or microscopy, irrespective of the re-
gion of infection. Generalization of the results to all
Schistosoma species may be difficult as in the study pre-
sented here only eggs of S. mansoni were detected by
microscopy. A minimum amount of two millilitre of
serum is required for sufficient diagnostic accuracy.
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